We are live on ! Find out more
HKPD

Cellyan Biotechnology
HKPD

6 hedge funds and large institutions have $93.5K invested in Cellyan Biotechnology in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

68% more capital invested

Capital invested by funds: $55.8K → $93.5K (+$37.7K)

50% more funds holding

Funds holding: 4 → 6 (+2)

0.2% more ownership

Funds ownership: 0.47% → 0.67% (+0.2%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$25.5K
2
VNA
Valley National Advisers
Pennsylvania
+$16.1K
3
TSS
Two Sigma Securities
New York
+$12.8K
4
TRCT
Tower Research Capital (TRC)
New York
+$386

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$16.2K
2
CS
Clear Street
New York
-$4.57K
3
Jane Street
Jane Street
New York
-$4.53K

HKPD Hedge Fund Activity: Q2 2025 in Review

6 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q2 2025, worth a combined $93.5K — up 68% from $55.8K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new HKPD positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, adding an estimated $25.5K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $16.2K sold.

  • 6 institutional investors held Cellyan Biotechnology (HKPD) as of Q2 2025, up from 4 in Q1 2025.
  • Funds reported $93.5K of Cellyan Biotechnology stock for Q2 2025, up 68% quarter-over-quarter.
  • 3 funds opened new Cellyan Biotechnology positions in Q2 2025 and 1 closed out, a net change of +2 holders.
  • The largest Cellyan Biotechnology buyer in Q2 2025 was UBS Group, an estimated $25.5K added.
  • The largest Cellyan Biotechnology seller in Q2 2025 was Warberg Asset Management, an estimated $16.2K sold.

Based on aggregated 13F filings for Q2 2025.